Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Lymphatic malformations occur when the body's lymphatic fluid channels do not develop properly, leading to fluid-filled lumps that can cause pain and swelling. Many of these malformations are caused by a change in a gene called PIK3CA. This trial is testing whether a medicine called alpelisib can help treat this condition. The study involves both children and adults. In the first stage, researchers will test different doses of the medicine to find the safest and most effective amount. In the second stage, participants will be randomly chosen to receive either alpelisib or a dummy treatment (placebo) to confirm how well it works. Babies and young children under six may receive the real medicine directly in an open-label group. Researchers will use body scans and symptom checks over 24 weeks to see if the medicine shrinks the lumps and improves quality of life.
At a glance
What is this study about?
The lymphatic system is a network of tubes and glands that helps balance fluid and fight infections in the body. In people with lymphatic malformations, some of these vessels do not form properly before birth. This leads to soft, spongy lumps or swellings that can cause pain, infections, and movement difficulties. Many people with this condition have a tiny change in a gene called PIK3CA, which makes the fluid vessels grow abnormally.
Alpelisib is a medicine designed to block the overactive signals caused by this gene change. By calming these signals, researchers hope the medicine can shrink the malformations and relieve symptoms. Currently, people often rely on repeated surgeries or injection treatments to drain or shrink the lumps, which do not always offer lasting relief.
This study is important because it tests whether a simple medicine taken by mouth could offer a better, non-surgical treatment option. Because it welcomes participants of all ages, from infants to older adults, the trial could help doctors understand how to treat this condition across a person's entire lifetime.
Key takeaways
- Tests whether the drug alpelisib can shrink lymphatic malformations caused by a PIK3CA gene change.
- Open to patients of all ages, from newborn babies to older adults.
- Lasts for 24 weeks initially, with options to continue treatment in an extension phase.
- Some participants may receive a dummy pill (placebo) during the 24-week test period.
- Participation is voluntary and includes regular scans and health monitoring.
Who may be eligible?
You or your child may be able to join if you have a doctor-confirmed lymphatic malformation that causes bothersome symptoms, along with a confirmed change in the PIK3CA gene. You must have at least one swelling that can be measured on a scan, and you must be able to swallow tablets, drink a liquid mixture, or take medicine through a feeding tube.
People cannot join if their condition is part of a broader overgrowth disorder (such as PROS) or other complex vessel conditions like Gorham-Stout disease. You will also not be able to take part if you have type 1 diabetes, poorly controlled type 2 diabetes, or a history of severe allergic skin reactions.
Participants must also agree not to have planned surgeries or injection procedures (like sclerotherapy) to shrink the lumps during the first 24 weeks of the study, and must not have previously taken alpelisib or similar drugs.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- You have a confirmed lymphatic malformation causing symptoms.
- A genetic test has confirmed a change in your PIK3CA gene.
- You have at least one lump that can be measured on an imaging scan.
- You can take medicines by mouth (tablets or liquids) or via a feeding tube.
- You are not planning surgery or injection procedures for your swelling over the next 24 weeks.
- You do not have type 1 diabetes or a history of severe skin conditions.
What does participation involve?
Taking part in this study lasts for at least 24 weeks, with the chance to continue in a longer extension phase. Depending on when you join, you will be in Stage 1 (dose-finding) or Stage 2 (testing the medicine against a placebo). In Stage 2, older children and adults have a two-in-three chance of receiving alpelisib and a one-in-three chance of receiving a placebo, while children under six receive the real medicine. You will take the medicine daily as a tablet, liquid drink, or through a feeding tube. You will need to visit the hospital clinic regularly for health checks, blood tests, and scans (such as an MRI) to measure your swellings, as well as keeping a diary of your symptoms.
Potential risks and benefits
Locations (61)
- UCSF Benioff Children s HospitalVerified postcodeOakland, United States· Recruiting
- Childrens Hospital of Orange CountyVerified postcodeOrange, United States· Recruiting
- Lucile Packard Childrens HospVerified postcodePalo Alto, United States· Recruiting
- Childrens National Medical CenterVerified postcodeWashington D.C., United States· Recruiting
- Nemours Childrens ClinicVerified postcodeJacksonville, United States· Recruiting
- Childrens Hosp Boston Dept of HemeVerified postcodeBoston, United States· Recruiting
- WA Uni School Of MedVerified postcodeSt Louis, United States· Recruiting
- University of North Carolina at Chapel HillVerified postcodeChapel Hill, United States· Recruiting
- Cinn Children Hosp Medical CenterVerified postcodeCincinnati, United States· Recruiting
- Univ Hospital Of ClevelandVerified postcodeCleveland, United States· Recruiting
- Cleveland Clinic FoundationVerified postcodeCleveland, United States· Recruiting
- Nationwide Children s HospitalVerified postcodeColumbus, United States· Recruiting
Common questions
What is alpelisib?
Alpelisib is a targeted medicine that blocks a specific protein pathway in the body. It aims to stop abnormal fluid vessels from growing and help shrink existing swellings.
Will I definitely receive the real medicine?
In Stage 1, all participants receive alpelisib. In Stage 2, adults and children over six are randomly assigned by a computer to receive either alpelisib (2 in 3 chance) or a placebo (1 in 3 chance). Children under six in Stage 2 will receive the real medicine.
How is the medicine taken?
The medicine comes as tablets that can be swallowed, or as granules and liquids that can be mixed into a drink or given through a feeding tube.
Can my young child take part?
Yes. The trial is open to people of all ages, from newborns up to 100 years old, provided they meet the health and gene-test requirements.
Can I leave the study early if I want to?
Yes. You or your child can leave the study at any point without giving a reason, and your regular medical care will continue as normal.
How to find out more
Novartis Pharmaceuticals
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.